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ABSTRACT
      The genus Ebola virus first was recognized in 1976, when two outbreaks occurred in Zaire and Sudan. 
Ebola virus disease (EVD) is a highly contagious disease that can affect both human and nonhuman 
Bundibugyo ebolavirus (BEBOV) and Reston ebolavirus (REBOV) are five members of the Filoviridae 
family that can cause haemorrhagic fever. EVD is transmitted by direct contact with contaminated blood or 
other biological fluids of the infected animals such as chimpanzees, gorillas, fruit bats, monkeys, forest antelope 
and porcupines found ill or dead or in the rainforest. Ebola is responsible for different clinical futures that can be 
ranged from fever, headache, arthralgia, myalgia, abdominal pain, anorexia and vomiting to severe respiratory 
disorders, viral hemorrhagic fever, cardio-vascular disorders and hypovolaemic shock. Although there is no 
specific treatment for EVD, considerable advances like use of monoclonal antibody, intefron and Favipiravir/T-
705 as effective chemotherapeutic agent in treatment of EBV have been made. To date, 25 outbreaks of EVD 
have been reported. Hence, EVD as a zoonotic disease should be more focused not only in endemic area but also 
in throughout the world. Awareness of the disease and routes of transmission and also continuous surveillance to 
combat disease and outbreaks is necessary.
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INTRODUCTION 
      Ebola virus as a causative agent of a severe form 
of viral haemorrhagic fever has drawn international 
attention particularly for the largest outbreaks in 
West African countries. Ebola haemorrhagic fever 
(EHF) is a zoonosis disease that can affect both 
human and nonhuman primates and caused by 
members of the Filoviridae family: Zaire ebolavirus 
(ZEBOV), Sudan ebolavirus (SEBOV), Côte 
ebolavirus (BEBOV) and Reston ebolavirus 
(REBOV) [1]. Ebola virus was first documented in 
1976 in Republic of the Congo near the Ebola River 
[2]; since then, outbreaks have been reported. So far 
about 25 outbreaks of Ebola have been 
approximately recognized that all occurring in 
Africa, with fatality rates of 25% to 90% [3, 4]. 
Ebola virus disease (EVD) which was known as 
EHF is a highly contagious anthropozoonotic 
disease that can cause by direct contact with 
contaminated blood or other biological fluids of the 
infected animals such as chimpanzees, gorillas, fruit 
bats, monkeys, forest antelope and porcupines found 
ill or dead or in the rainforest [2, 5, 6]. The Ebola 
virus with a relatively high mortality rate 20-90% 
(depending on the virus species) and the possibility 
of misuse as a biological weapon is a serious threat 
to the worldwide. The natural reservoir host of 
Ebola virus remains unknown. However, on the 
basis of evidence and the nature of similar viruses, 
many researchers believe that this virus is animal-
borne and bats are the most likely reservoir [7]. 
Despite ongoing efforts to recognize the molecular 
biology and pathogenesis of Ebola virus during the 
past two decades, there are ambiguities 
regarding virulence factors, host responses, 
treatment methods and vaccines of EV. The purpose 
of this review is to present essential and up-to-date 
information required to identify, management, 
prevention and treatment of EVD.
